Welcome to our dedicated page for Sigyn Therapeutics SEC filings (Ticker: SIGY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sigyn Therapeutics, Inc. (SIGY) SEC filings page on Stock Titan is intended to help investors review the companys regulatory disclosures alongside AI-generated insights. Sigyn Therapeutics describes itself as a development-stage medical technology company focused on dialysis-like blood purification therapies, including Sigyn Therapy for pathogen-associated inflammatory disorders and oncology-support platforms such as ImmunePrep, ChemoPrep, and ChemoPure.
Through filings such as the annual report on Form 10-K and registration statements referenced in company press releases, investors can examine details about Sigyn Therapeutics business description, risk factors, development plans, and capital structure. For example, the company has publicly noted the filing of its Form 10-K for the year ended December 31, 2023, and the submission of a Form S-1 registration statement to support a proposed financing and potential listing on The Nasdaq Capital Market.
On this page, real-time updates from the SECs EDGAR system are paired with AI-powered summaries that aim to clarify the key points of lengthy documents. For development-stage issuers like Sigyn Therapeutics, this can include explanations of planned first-in-human feasibility studies of Sigyn Therapy in end-stage renal disease patients with endotoxemia and concurrent inflammation, as described in company communications, as well as context around reverse stock split actions and related share structure changes.
Investors can use this resource to quickly locate 10-K annual reports, 10-Q quarterly reports, registration statements, and other material filings associated with SIGY. AI analysis highlights sections related to the companys therapeutic pipeline, regulatory strategy, and financing plans, while also making it easier to track changes in risk disclosures and capital markets activity over time.
Sigyn Therapeutics, Inc. entered into three one-year convertible note purchase agreements with institutional investors, raising small amounts of short-term funding through unregistered securities.
On February 12, 2026, the company issued two convertible notes: one to Brio Capital Master Fund, Ltd and one to Osher Capital Partners, LLC, each with a principal amount of
Each note bears interest at
Sigyn Therapeutics, Inc. received an amended Schedule 13G/A showing that Brio Capital Master Fund Ltd., together with Brio Capital Management LLC, reports beneficial ownership of 160,537 shares of common stock, representing 9.99% of the class.
The filing explains that this amount includes 84,608 shares of common stock plus additional shares issuable from warrants, convertible notes and convertible preferred shares, subject to a 9.99% beneficial ownership cap. The percentage is based on 1,605,377 shares outstanding as of November 14, 2025. The reporting persons certify the holdings are not for the purpose of changing or influencing control of the company.
Sigyn Therapeutics (SIGY) filed its Q3 2025 10‑Q, reporting continued losses and limited liquidity. The company posted a net loss of $578,503 for the quarter and $2,698,254 for the nine months ended September 30, 2025. Cash was $85,571 with total assets of $135,571, against total liabilities of $6,052,780, resulting in a stockholders’ deficit of $(5,917,209). The filing states substantial doubt about the company’s ability to continue as a going concern.
Sigyn had no revenue and funded operations through convertible debt and a Regulation D offering. In 2025 it sold 69 Units for $379,717 aggregate principal (cash received $345,197) and issued additional 2025 convertible notes, including variable‑price notes that created a $181,362 derivative liability. Key noteholders extended maturities to December 31, 2027 in exchange for original issue discounts totaling $737,786. An inducement to preferred holders resulted in a $845,901 expense.
The company is repositioning around CardioDialysis and filed a trademark to support the strategy shift. As of November 14, 2025, common shares outstanding were 1,605,377.